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Oberaigner et al. 2011 present an update of the Tyrol
cohort study of screening for prostate cancer utilizing an
observational design with ﬁve additional years of follow-
up. The study was initiated in 1993 by offering a free PSA-
test to all men in the age group 45–74. It is estimated that
about 75% of the men had undergone at least one time PSA
testing. The study shows for the observation period of
2004–2008 in men above the age of 50, a 30% signiﬁcant
reduction of prostate cancer mortality with respect to the
reference period of 1993–1998. This effect increases
sequentially during the 5-year observation period chosen
by the authors. Also, different risk reductions were seen for
different age cohorts. The effect of screening on prostate
cancer mortality seen in this study is in line with obser-
vations obtained in the European Randomized study of
Screening for Prostate Cancer were mortality reduction in
men who were in fact screened amounts to 27% after
9 years and 44% after 14 years of follow-up (Schro ¨der
et al. 2009, Hugosson et al. 2010).
The authors are correct when they claim that the pre-
sented data ‘permit to investigate the effect of PSA
screening in a real life situation’. Also, the set-up allows a
comparison between Tyrol and the rest of Austria. How-
ever, inherent to the study are also all the potential
disadvantages of a cohort study with poor deﬁnition of a
number of parameters that could inﬂuence the endpoint of
prostate cancer mortality. As a consequence, the study
remains uninformative with respect to the true value of
screening, to future policy making in terms of screening
procedures, as well as on potential beneﬁts and harms.
The authors did not clarify the trend in mortality from
PCA which occurred before the start of the program. In
fact, in the Tyrol area an increase was observed up to 1990
when a decrease started. In the rest of Austria, a rather ﬂat
trend was observed up to 2000 when a slight decrease
began. The reason of the different trends before the
beginning of the PSA testing is not explained. Have factors
not related to PSA played a role? This could partially
explain the slope of the decrease afterward.
The methodology used is based on prostate cancer
mortality estimates in the region of Tyrol and the region of
Austria without Tyrol. Three different cohorts based on age
and the time of evaluation are formed and provide the basis
for this evaluation.
The authors carried out an age-period cohort analysis in
order to disentangle the net effect of time periods. The
results are interesting, showing no reduction in PCA mor-
tality in the Tyrol study in the ﬁrst period (1994–1998) as
compared to the reference period (1983–1993) (estima-
tor = 0.97, 95% CI 0.84–1.12). A reduction in mortality
occurred, although not statistically signiﬁcant, in the sec-
ond period (1999–2003) (estimator = 0.86, 95% CI
0.72–1.04) and ﬁnally the decrease reached the statistical
signiﬁcance in the third period (2004–2008) (estima-
tor = 0.70, 95% CI 0.57–0.87). This pattern supports the
hypothesis that the reduction in mortality is really the
consequence of the introduction of PSA testing. In fact,
either from a theoretical point of view or as observed in the
ERSPC study (Schro ¨der et al. 2009), the effect of early
diagnosis on mortality can not be expected in the ﬁrst
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1235 years after the start of the programs. It is worth nothing
that this analysis gives a different and more realistic
interpretation from what was reported in 2001 (Bartsch
et al. 2001). In that paper, a reduction in mortality in the
Tyrol area was reported since 1995 (i.e. 2 years after the
start of the program) and was interpreted as a consequence
of PSA testing.
Some of the limitations of the protocol and present
report are described in the paper. These include the inabil-
ity to evaluate the confounders in relation to the endpoint
such as the use of a historical control group, the absence of
a validation of the causes of death assigned in the cancer
registry and the lack of detailed knowledge about the
volume and timing of PSA testing, as well as the limited
knowledge that can be accumulated on the harms of
screening. These limitations and several others mentioned
in this commentary are essential for the understanding of
the screening process and for the potential introduction of
screening as a healthcare policy.
• The number of participants remains unknown and this
prohibitsthecalculationofdetectionratesperPSAranges
and per age groups. It would be very interesting to learn
about the effect of the application of age-speciﬁc
reference range and speciﬁcally about the effect of
cutting these in half after October 19, 1996. This comes
down to extremely low cut-off values for biopsy indica-
tions for PSA per age group between 1.25 and 3.25. The
effectintermsofdiagnosisofaggressivelesionsandover
diagnosis remains unfortunately unknown.
• The absence of data on the frequency of testing,
participation rates and biopsy compliance make it
impossible to put the data into the context of the
controlled trials. During a period where screening for
prostate cancer is scrutinized and criticized worldwide,
the knowledge provided in this paper is non-contribu-
tory in too many important aspects.
• The authors state by citing the paper of Pelzer et al.
(2008) that overdiagnosis may have been in an
acceptable range of 8–17% based on radical prostatec-
tomy ﬁndings. This is very unlikely if one considers
that the incidence of prostate cancer given in Fig. 3
increased by a factor of 4 from the baseline ﬁgure of
about 30/100,000 in 1983 to about 120/100,000 in
2003. Unfortunately, the complete absence of data on
the frequency and the results of biopsies in relation to
different levels of PSA make a proper appreciation
impossible.
• As mentioned, the effect on prostate cancer mortality is
evaluated by age groups and time periods of follow-up.
The study shows an increasing effect with increasing
age at the time of death. Unfortunately, this can not be
related to the time of diagnosis or inclusion. It is
probable that the increase of the effect obtained when
people older than 74 are excluded from the analysis is
the consequence of the fact that part of the men older
than 74 did not have the opportunity to be screened
because they fell out of the target population at the time
of the program started. Again, this data support the role
of PSA in reducing the speciﬁc mortality.
• In measuring the effect on prostate cancer mortality, the
added 5-year time period 2004–2008 is utilized. This
again creates an artifact which is well demonstrated in
the evaluation of the results of the ERSPC study
(Schro ¨der et al. 2009) by Hanley (2010). Considering
only the last time period of 5 years instead of studying
a cumulative effect over the whole time period must
show a more favorable mortality reduction because the
early periods where no effect is seen are excluded. On
the other hand, the increasing effect over time is an
important observation. In this setting, it gives a rough
indication of the time period needed to evaluate
screening for prostate cancer. The presented data
suggest that even 16 years after the initiation of the
study the mortality reduction seen does not level-off.
The latter would be an indication of the ultimate
follow-up period needed to evaluate prostate cancer
screening studies.
This observational cohort study provides additional
evidence for an effect of PSA-driven screening on prostate
cancer mortality. A number of important confounders
mentioned and the potential effectiveness of treatment
regimens applied to cancer patients remain unknown. On
the other hand, the continuous increase of the prostate
cancer mortality reduction over time lends credibility to an
effect of PSA-driven screening, even without knowledge of
essential details on the procedures followed in this study.
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